Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

13 Canadian Crypto ETFs (Updated 2024)

Mark These Tax-loss Selling Dates on Your Calendar (Updated 2024)

Investing in Graphene Companies (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Can You Invest in Elon Musk’s Neuralink? (Updated 2024)

Trending Press Releases

Radiopharm achieves Nasdaq listing of ADS

US$30 Million Prepayment Term Sheet and Offtake Agreement Executed with a Global Commodities Trader

Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

Mawson Finland Limited Identifies Compelling Soil Geochemical Targets for Follow-Up

COLDry Fertiliser JV Seed Funding & Working Capital Secured

Stardust Power Acquires Site, Receives Key Permit And Receives Approval For Major Construction To Commence

More Press Releases
Trending Companies

First Helium

HELI:CA

Black Swan Graphene

SWAN:CC

Purpose Bitcoin ETF

BTCC:CA

Soma Gold Corp.

SOMA:CA
More Companies
Trending Reports

2025 Gold Outlook Report

2025 Gold Outlook: Australia Edition

2025 Uranium Outlook

2025 Crypto Outlook Report

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Bristol-Myers Squibb

NYSE:BMY
Press Releases

Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Bristol Myers Squibb Announces Leadership Transition Plan

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Interactive Chart

×